دورية أكاديمية
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study
| العنوان: | Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study |
|---|---|
| المؤلفون: | Van Ryckeghem, F., Haverbeke, C., Wynendaele, W., JERUSALEM, Guy, Somers, L., Van den broeck, A., Vingerhoedt, S., Van Belle, S. |
| المصدر: | Supportive Care in Cancer, 27, 1099-1108 (2019) |
| بيانات النشر: | Springer Verlag, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Breast cancer, Chemotherapy, Febrile neutropenia, Granulocyte colony-stimulating factor, Prophylaxis, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie |
| الوصف: | Purpose: To prevent febrile neutropenia (FN), European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend primary prophylaxis with granulocyte colony-stimulating factors (PPG) for patients at high risk (≥ 20%) of FN. In Belgium, the use of PPG is restricted by specific reimbursement criteria. The impact of these criteria on PPG use and adherence to guidelines is unknown. Methods: This multicentre, cross-sectional, observational study aimed to describe PPG use by FN risk category in breast cancer patients who were scheduled to receive myelosuppressive chemotherapy in outpatient clinics in Belgium during a 2-week period between 13 October and 12 December 2014. Results: In total, 490 patients were enrolled. Median age was 57.0 years. Based on their chemotherapy regimen, 53.9, 5.1 and 41.0% of patients were at a low, intermediate and high risk of FN, respectively. Overall, 39.8% of patients received PPG (17.0, 12.0 and 73.1% of those receiving low-, intermediate- and high-risk regimens, respectively). In the high-risk category, PPG was used in 89.9% of dose-dense and in 25.0% of classical chemotherapy regimens. PPG use was adherent to EORTC guidelines in 75.3% of patients (30.6% appropriate use, 44.7% appropriate non-use). EORTC guidelines would recommend PPG use in 46.1% of this study population (n = 226), and its use was reimbursable in Belgium in 76.1% of these patients (n = 172), but only 66.4% of them received PPG (n = 150). Conclusions: Both Belgian reimbursement criteria and physician decision-making led to a proportion of patients for whom PPG treatment was recommended but finally not receiving it. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article |
| اللغة: | English |
| Relation: | urn:issn:0941-4355; urn:issn:1433-7339 |
| DOI: | 10.1007/s00520-018-4399-3 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/236100 |
| حقوق: | restricted access http://purl.org/coar/access_right/c_16ec info:eu-repo/semantics/restrictedAccess |
| رقم الأكسشن: | edsorb.236100 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1007/s00520-018-4399-3 |
|---|